FWBI Stock Overview
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
First Wave BioPharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.90 |
52 Week High | US$65.00 |
52 Week Low | US$2.75 |
Beta | 1.21 |
1 Month Change | -40.21% |
3 Month Change | -16.19% |
1 Year Change | -94.63% |
3 Year Change | -99.99% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections
Jan 04AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients
Nov 30Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?
Nov 19Shareholder Returns
FWBI | US Biotechs | US Market | |
---|---|---|---|
7D | -15.2% | -4.2% | -3.7% |
1Y | -94.6% | -2.0% | 20.5% |
Return vs Industry: FWBI underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: FWBI underperformed the US Market which returned 20.2% over the past year.
Price Volatility
FWBI volatility | |
---|---|
FWBI Average Weekly Movement | 18.1% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FWBI's share price has been volatile over the past 3 months.
Volatility Over Time: FWBI's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 9 | James Sapirstein | www.firstwavebio.com |
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis.
First Wave BioPharma, Inc. Fundamentals Summary
FWBI fundamental statistics | |
---|---|
Market cap | US$5.87m |
Earnings (TTM) | -US$16.10m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs FWBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FWBI income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$16.10m |
Earnings | -US$16.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -7.95 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 17.0% |
How did FWBI perform over the long term?
See historical performance and comparison